Congratulations to BoardProspects Member Michal Preminger on Her Appointment to the Board of Compugen (NASDAQ: CPGN)!
BoardProspects would like to congratulate Member Michal Preminger on her appointment to the Board of Directors of Compugen (NASDAQ: CPGN). Dr. Preminger is the Executive Director at Harvard University Office of Technology Development's Harvard Medical School site. Dr. Preminger is also a member of the board of directors of BioArray Genetics and Israel Brain Technologies, and a member of the Scientific Advisory Board at FutuRx (a partnership between Takeda Pharmaceuticals, Johnson & Johnson and Orbimed Ventures) and Prize4Life.
Compugen is a genomics-based drug and diagnostic discovery company.
Login to comment.